Therefore, we examined the effect of DNase I in vitro on selected GCT cell line models and subsequently we designed the preclinical proof-of-concept study to evaluate the effect of DNase I treatment alone and in combination with CDDP on the xenografts derived from the chemoresistant variant of the human EC cell line NTERA-2 CisR. This evidence concerns the gene DNASE1 and granular cell tumor.